Lung disease in rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 20, Issue 3, 2008, Pages 340-346

  Nannini, Carlotta ^a   Ryu, Jay H ^a   Matteson, Eric L ^a,b  

^a MAYO CLINIC   (United States)

^b NONE   (United States)

Author keywords

Clinical features; Epidemiology; Lung disease; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BLEOMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

B LYMPHOCYTE; CELL INFILTRATION; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; HUMAN; IMMUNE RESPONSE; INTERSTITIAL PNEUMONIA; LUNG DISEASE; LUNG TOXICITY; MAST CELL; MORTALITY; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PLEURA DISEASE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; SURVIVAL; T LYMPHOCYTE;

ARTHRITIS, RHEUMATOID; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE;

EID: 41649121668     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282f798ed     Document Type: Review

References (73)

1. Turesson C, O'Fallon WM, Crowson CS, et al. Occurrence of extra-articular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002; 29:62-67.
2. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48:54-58.
3. Turesson C, Jacobsson L, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003; 62:722-727.
4. Dong Soon K. Interstitial lung disease in rheumatoid arthritis: recent advances. Pulm Med 2005; 12:346-353.
5. Anaya JM, Diethelm L, Ortiz LA, et al. Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 1995; 24:242-254.
6. Turesson C, Jacobsson LTH. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004; 33:65-72.
7. Klareskog L, Pedereson M, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to auto-antigens modified by citrullination. Arthritis Rheum 2006; 54:38-46.
8. Michel JJ, Turesson C, Lemster B, et al. CD56-expressing T cells that have features of senescence are expanded in rheumatoid arthritis. Arthritis Rheum 2007; 56:43-57. Premature immunosenescence is a characteristic of T cells in RA and is particularly pronounced in patients with extraarticular disease including lung disease.
9. Dowson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography and pulmonary function tests. Thorax 2001; 56:622-627.
10. Cortet B, Perez T, Roux N, et al. Pulmonary function tests and high resolution computer tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56:596-600.
11. Gabby E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997; 156:528-535.
12. Turesson C, Jacobsson L, Bergstrom U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford) 1999; 38:668-674.
13. Hakala M. Poor prognosis in patients with rheumatoid arthritis hospitalized for interstitial lung fibrosis. Chest 1988; 93:114-118.
14. Myllykanges-Lousujarvi RA, Aho K, et al. Mortality in rheumatoid arthritis. Semin Arthritis Rheum 1995; 25:193-202.
15. Thomas E, Symmons DPM, Brewster DH, et al. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year follow-up study. J Rheumatol 2003; 30:958-965.
16. Michalski JP, McCombs CC, Scopelatis E, et al. Alpha 1 antitrypsin phenotypes including M subtypes in pulmonary disease associated with rheumatoid arthritis and systemic sclerosis. Arthritis Rheum 1986; 29:586-591.
17. Sugiyama Y, Ohno S, Kano S. Diffuse panbronchiolitis and rheumatoid arthritis: a possible correlation with HLA-B54. Intern Med 1994; 33:612-614.
18. Charles PJ, Sweatman MC, Marckwick JR, et al. HLA-B40: a marker for susceptibility to lung disease in rheumatoid arthritis. Dis Markers 1991; 9:97-101.
19. Normann MR, Mowat AP, Hutchinson DCS. Molecular basis, clinical consequences and diagnosis of alpha 1 anti trypsin deficiency. Ann Clin Biochem 1997; 34:230-246.
20. Clarkson R, Bate AS, Grennan DM, et al. DQw7 and C4B null allele in rheumatoid arthritis and Felty's syndrome. Ann Rheum Dis 1990; 49:976-979.
21. Radoux V, Menard HA, Begin R, et al. Airways disease in rheumatoid arthritis patients. Arthritis Rheum 1987; 30:249-256.
22. Hillarby MC, Mcmahon MJ, Grennan DM, et al. HLA associations in subjects with rheumatoid arthritis and bronchiectasis but not with other pulmonary complications of rheumatoid disease. Br J Rheumatol 1993; 32:794-797.
23. Travis WD, Matsui K, Moss J, et al. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns. Survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathos 2000; 24:19-33.
24. Geddes DM, Webley M, Emerson PA. Airways obstruction in rheumatoid arthritis. Ann Rheum Dis 1979; 38:222-225.
25. Vergnenegre A, Pugnere N, Antonimi MT, et al. Airways obstruction and rheumatoid arthritis. Eur Resp J 1997; 10:1072-1078.
26. Geterud A, Ejnell H, Mansson I, et al. Severe airways obstruction caused by laryngeal rheumatoid arthritis. J Rheumatol 1986; 13:948-951.
27. Weyand CM, Schmidt D, Wagner U, et al. The influence of sex the phenotype of rheumatoid arthritis. Arthritis Rheum 1998; 41:817-822.
28. Yamadori I, Fujiuta J, Kajitani H, et al. Lymphocyte subsets in lung tissues of non specific interstitial pneumonia and pulmonary fibrosis associated with collagen vascular disorders: correlation with CD4/CD8 ratio in bronchoalveolar lavage. Lung 2000; 178:361-370.
29. Magro CM, Marsh CB, Allen JN, et al. The role of antiendothelial cell antibody-mediated microvascular injury in the evolution of pulmonary fibrosis in the setting of collagen vascular disease. Am J Pathol 2007; 127:237-247. Microvascular injury is a feature of lung disease in several forms of pulmonary fibrosis in autoimmune disorders. Antiendothelial antibody is strongly expressed, as in other tissues in RA including the synovium and appears to be cerebral to the vascular injury seen in CVDs.
30. Turesson C, Matteson EL, Colby TV, et al. Increased CD4+ cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum 2005; 52:73-79.
31. Vallejo AN, Weyand CM, Goronzy JJ. Functional disruption of CD28 gene transcriptional initiator in senescent T cells. J Biol Chem 2001; 276:2565-2570.
32. Kotzin BL. The role of B cells in the pathogenesis of rheumatoid arthritis. J Rheumatol 2005; 32 (Suppl 73):14-18.
33. Atkins SA, Turesson C, Myers JL, et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 2006; 54:635-641.
34. Bongartz T, Cantaert T, Atkins SA, et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2007; 46:70-75.
35. Atkins SA, Matteson EL, Myers JL, et al. Morphologic and quantitative assessment of mast cells in rheumatoid arthritis associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Ann Rheum Dis 2006; 65:677-680.
36. Walls AF, Bennett AR, Godfrey RC, et al. Mast cell tryptase and histamine concentrations in bronchoalveolar lavage fluid from patients with interstitial lung disease. Clin Sci (Lond) 1991; 81:183-188.
37. Moyron-Quiroz JE, Ranger-Moren J, Kusser K, et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nature Med 2004; 10:927-934.
38. Selman M, King TE Jr, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136-151.
39. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 1998; 19:667-685.
40. Chapman PT, O'Donnel JL, Moller PW. Rheumatoid pleural effusion: response to intrapleural corticosteroid. J Rheumatol 1992; 19:478-480.
41. Hunninghake GW, Fauci AS. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 1979; 119:471-494.
42. Walker WC, Wright V. Pulmonary lesions and rheumatoid arthritis. Medicine 1968; 47:501-520.
43. Rajasekaran A, Shovlin D, Saravanan V, et al. Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenetic fibrosing alveolitis over 5 years. J Rheumatol 2006; 33:1250-1253.
44. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345:517-525.
45. Strange C, Highland KB. Interstitial lung disease in the patient who has connective tissue disease. Clin Chest Med 2004; 24:549-559.
46. Tansey D, Wells AU, Colby TV, et al. Variations in histologica patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004; 44:585-596.
47. Lee HK, Kim DS, Yoo B, et al. Histologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127:2019-2027.
48. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157:1999-2203.
49. Nicholson AG, Colby TV, Dubois RM, et al. The prognostic significance of histologic patterns of interstitial pneumonia in patients presenting with the clinical entity of cryptogenetic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162:2213-2217.
50. Cortet B, Flipo RM, Remy-Jardin M, et al. Use of high resolution computer tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1995; 54:815-819.
51. Haykawa H, Sato A, Imokawa S, et al. Bronchiolar disease in rheumatoid arthritis. Am J Respir Crit Care Med 1996; 154:1531-1536.
52. Udayakumar N, Venkatesan S, Rajendiran C. Pulmonary hypertension in rheumatoid arthritis. Relation with the duration of the disease. Int J Cardiol 2007 [Epub ahead of print]. As shown by the authors, pulmonary hypertension is a heretofore underrecognized complication of RA with a significant impact on disease-related morbidity.
53. Dowson JK, Goodson NG, Graham DR, et al. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology 2000; 39:1320-1325.
54. Carroll GJ, Thomas R, Phatours CC, et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 1994; 21:51-54.
55. Dowson JK, Graham DR, Desmond J, et al. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology 2002; 41:262-267.
56. Kamata Y, Nara H, Kamimura T, et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Inter Med 2004; 43:1201-1204.
57. Schoe A, Van Der Laan-Baalbergen NE, Huizinga TWJ, et al. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum 2006; 55:157-159.
58. Roos JCP, Chilvers ER. Interstitial pneumonitis and antitumor necrosis factor-α therapy. J Rheumatol 2007; 34:1-3.
59. Ostor AJK, Crisp AJ, Somerville MF, et al. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 2004; 329:1266.
60. Hagiwara K, Sato T, Takagi-Kobayashi S, et al. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol 2007; 34:1151-1154.
61. Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol 2006; 33:1189-1193.
62. Kuroki M, Noguchi Y, Schimono M, et al. Repression of bleomycin-induced pneumopathy by TNF. J Immunol 2003; 170:567-574.
63. Drent M, du Bois R, et al. Recent advances in the diagnosis and management of nonspecific interstitial pneumonia. Curr Opin Pulm Med 2003; 9:411-417.
64. Caples SM, Utz JP, Allen MS, et al. Thoracic surgical procedures in patients with rheumatoid arthritis. J Rheumatol 2004; 31:2136-2141.
65. Vassallo R, Thomas CF. Advances in treatment of rheumatic interstitial lung disease. Curr Opin Rheumatol 2004; 16:186-191.
66. Walter N, Collard HR, King TE Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3:330-338.
67. Collard HR, Ryu JH, Douglas WW, et al. Combined corticosteroids and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004; 125:2169-2174.
68. Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis associated pulmonary fibrosis to tumor necrosis factor alfa inhibition. Chest 2002; 122:1093-1096.
69. Antoniou KM, Mamaulaki M, Malageri K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheum 2007; 25:23-28.
70. Dellaripa P, Fry T, Willoughby J, et al. The treatment of interstitial lung disease associated with rheumatoid arthritis with infliximab. Chest 2003; 124:109S.
71. Garcia-Vicuna R, Ortiz AM, Carmona L, et al. Inflammatory interstitial lung disease in rheumatoid arthritis patients treated with biologic treatment. Incidence and mortality rates compared with patients receiving biologics. Ann Rheum Dis 2005; 64 (Suppl III):470.
72. Brulhart L, Waldburger J-M, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006; 65:974-975.
73. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007; 82:916-919.